A consortium led by KKR and Warburg Pincus has made a non-binding bid for Gerresheimer AG, a company known for producing pens used in administering weight loss medications like Wegovy. The bid is reportedly close to 90 euros per share, valuing Gerresheimer at approximately 3.1 billion euros ($3.37 billion), a significant increase from its market value of 2.65 billion euros as of last Friday.

However, the potential takeover is not assured, and the process may take several weeks to unfold. Sources familiar with the situation, who requested anonymity, indicated that discussions are still in the early stages. Both KKR and Warburg Pincus have declined to comment, and Gerresheimer has not responded to inquiries.

Following the news of the bid, Gerresheimer's shares experienced a rise of up to 5.5%. The company had previously announced that it was in preliminary discussions with private equity investors regarding a potential sale, emphasizing that these talks were informal and non-binding.

In a statement from February, Gerresheimer noted that it was too early to determine if a public takeover offer would materialize. The interest from KKR and Warburg Pincus comes after activist investor Ricky Chad Sandler acquired a 5.43% stake in the company in October 2024.

Recently, Gerresheimer revised its revenue guidance for 2025, cutting its expectations due to weak demand in its cosmetics and food and beverage sectors. The company now anticipates organic revenue growth of 3% to 5%, down from an earlier forecast of 7% to 10%. It has maintained its guidance for an adjusted core profit margin of around 22%.

Bloomberg was the first to report on the consortium's interest in acquiring Gerresheimer.